Outcome of patients with acute myelogenous leukemia after second salvage therapy

Cancer

Volumn 104, Issue 3, 2005, Pages 547-554

  Giles, Francis ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Verstovsek, Srdan ^a   Bueso Ramos, Carlos ^a   Shan, Jianqin ^a   Pierce, Sherry ^a   Garcia Manero, Guillermo ^a   Keating, Michael ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Complete response; Cytosine arabinoside; Salvage therapy

Indexed keywords

CYTARABINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 22544462799     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21187     Document Type: Article

References (14)

1. Giles F, Keating A, Goldstone A, Aviv I, Willman C, Kantarjian H. Acute myeloid leukemia. Hematology. 2002;2002:73-110.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medial Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
3. Leith C, Kopecky K, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group study. Blood. 1997;89:3323-3329.
4. Keating M, Cork A, Broach Y, et al. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res. 1987;11:119-133.
5. Hiddemann W, Martin W, Sauderland C, Heinecke A, Buchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia. 1990;4:184-188.
6. Angelov L, Brandwein J, Baker M, Scott G, Sutton D, Keating A. Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma. 1991;6:15-24.
7. Estey E. Treatment of relapsed or refractory acute myelogenous leukemia. Leukemia. 2000;14:476-479.
8. Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996;88:756.
9. Davis C, Rohatiner A, Lim J, et al. The management of recurrent acute myelogenous leukemia at a single center over a fifteen-year period. Br J Haematol. 1993;83:404-411.
10. Keating M, Kantarjian H, Smith T, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989;7:1071-1080.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
12. Cox D. The analysis of binary data. London: Chapman and Hall, 1970.
13. Cox D. Regression models and life tables. J R Stat Soc (B). 1972;34:187-220.
14. Grambsch P, Therneau T. Proportional hazard tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.